Pure Global AI
NCT06321666Recruitment Completed

Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone

Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone: A Whole Body MRI Study MILANO : RESPECT-MI
European Institute of OncologyClinicalTrials.govother
Verified
Study focus
Disease/Condition
Metastatic Breast Cancer
Drug/Device/Intervention
WB-MRI
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
European Institute of Oncology
Location
Milan, Italy
Timeline & enrollment
Phase
N/A
Start date
Sep 12, 2019
End date
Dec 31, 2024
Enrollment
58 participants
Primary outcome

Proportion of disease progression in bone metastasis identified by WB-MRI prior to CT scan

Summary

This is a non randomized, single arm study, where each patient will undergo imaging with
 Computed Tomography (CT) and Whole-body magnetic resonance imaging (WB-MRI) at different
 timepoint. The primary endpoint is time to progression as documented by CT or WB-MRI.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedMalignant neoplasm: Central portion of breastMalignant neoplasm: Overlapping lesion of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06321666
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06321666 through Pure Global AI's free database. This phase not specified trial is sponsored by European Institute of Oncology and is currently Recruitment Completed. The study focuses on Metastatic Breast Cancer. Target enrollment is 58 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.